• PDF / 169,109 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 1 Downloads / 124 Views

DOWNLOAD

REPORT

---

1 S

Third-degree atrioventricular block following off-label use: case report In a prospective study involving 41 COVID-19 patients, a patient [age and sex not stated] was described, who developed thirddegree atrioventricular block following off-label treatment with lopinavir/ritonavir for COVID-19. The patient was admitted in intensive care unit with COVID-19 infection. Therefore, the patient started receiving off-label treatment with lopinavir/ritonavir 200/50mg [route not stated] twice a day for 10 days. During the treatment patient developed a third-degree atrioventricular block secondary to lopinavir/ritonavir therapy. Hence, the patient’s lopinavir/ritonavir treatment was discontinued [duration of treatment to reaction onset and outcome not stated]. Beyls C, et al. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. Circulation: Arrhythmia and Electrophysiology 13: 803501888 e008798, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1161/CIRCEP.120.008798

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822